A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

• Main Authors: M. Domenica Cappellini, Vip Viprakasit, Ali T. Taher, Pencho Georgiev, Kevin H.M. Kuo, Thomas Coates, Ersi Voskaridou, Hong Keng Liew, Idit Pazgal-Kobrowski, G. L. Forni, Silverio Perrotta, Abderrahim Khelif, Ashutosh Lal, Antonis Kattamis, Efthymia Vlachaki, Raffaella Origa, Yesim Aydinok, Mohamed Bejaoui, P. Joy Ho, Lee Ping Chew, Ping Chong Bee, Soo Min Lim, Meng Yao Lu, Adisak Tantiworawit, Penka Ganeva, Liana Gercheva, Farrukh Shah, Ellis J. Neufeld, Alexis Thompson, Abderrahmane Laadem, Jeevan K. Shetty, Jun Zou, Jennie Zhang, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Matthew L. Sherman, Olivier Hermine, John Porter, Antonio Piga
• 格式: 雜誌
• 出版: 2020
• 主題: Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082380437&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/68472
• 機構: Chiang Mai University

Copyright © 2020 Massachusetts Medical Society. BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and red...